ASX Release
27 November 2026

ASX code: PIQ

Results of Share Purchase Plan

Proteomics International Laboratories Ltd (ACN 169 979 971) (**PIQ, Proteomics** or the **Company**), announces the results of its Share Purchase Plan (**SPP**), originally announced 2 November 2026, which closed on 25 November 2026. Capitalised terms used in this announcement have the same meaning as in the Share Purchase Plan Offer Booklet dated 4 November 2026 (**SPP Offer Booklet**), unless otherwise defined.

The SPP received support from eligible shareholders, with applications received totalling approximately A$0.97 million. All valid applications have been accepted in full and no scale back has been applied.

Directors of the Company Aaron Brinkworth and Paul House were eligible shareholders and able to participate in the SPP, with both subscribing for the maximum amount of A$30,000 each.

Shares were offered under the SPP at an issue price of $0.10, which represented a discount of 12.2% to the volume weighted average market price for the Company's Shares, calculated over the 5 days leading up to market close on Friday, 30 October, 2026 (record date) (5-day VWAP - A$0.1139), and a discount of 16.7% to the last closing price of the Shares on Friday, 30 October 2026 - A$0.12.

As outlined in the SPP Offer Booklet, the SPP Shares were to attract a free attaching Option for each Share subscribed and issued, subject to shareholder approval at the Annual General Meeting held 20 November 2026. As the resolution put to shareholders for the issue of free attaching Options was not carried, approval was not obtained and therefore no Options will be issued to participants in the SPP.

As per the timetable outlined in the SPP Offer Booklet, SPP Shares will be issued on Monday 30 November 2026.

CEO and Managing Director, David Morris commented, "On behalf of the Board, I would like to sincerely thank all shareholders who participated in and supported the Share Purchase Plan. We greatly appreciate your continued confidence in the Company and your ongoing support as we progress our strategy to commercialise our Promarker portfolio, and pursue the significant opportunities ahead for the Company."

The funds raised under the SPP will be directed towards commercial execution, including the Healius rollout, the expected launch of PromarkerEndo®, laboratory capacity, clinical evidence generation to support reimbursement activities and preparations for US market entry.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

For further information please contact:

David Morris CEO and Managing Director +61 8 9389 1992 | enquiries@proteomicsinternational.com
Jane Lowe Investor Relations, IR Department +61 411 117 774 | jane.lowe@irdepartment.com.au

Further information about the Company is available on the Company's website (see www.proteomicsinternational.com).

About Proteomics International Laboratories Ltd

Proteomics International is a Perth-based medical technology company specialising in proteomics, the study of proteins and their functions. The Company develops precision diagnostic tests and provides specialist bioanalytical services to improve the detection and management of disease.

Forward Looking Statements and Disclaimers

This announcement is for information purposes only and does not constitute a prospectus or prospectus equivalent document. It is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer to purchase or otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, nor shall there be any offer, sale, issuance or transfer of securities in any jurisdiction in contravention of any applicable law.

This announcement contains forward looking statements. Forward looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "forecast", "believe", "plan", "estimate", "expect" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions.

The forward looking statements in this announcement are based on current expectations, estimates, forecasts and projections about the Company and the industry in which it operates. They do, however, relate to future matters and are subject to various inherent risks and uncertainties. Actual events or results may differ materially from the events or results expressed or implied by any forward looking statements. The past performance of the Company is no guarantee of future performance.

Neither the Company nor any of its directors, officers, employees, agents or contractors makes any representation or warranty (either express or implied) as to the accuracy or likelihood of fulfilment of any forward looking statement, or any events or results expressed or implied in any forward looking statement, except to the extent required by law.

You are cautioned not to place undue reliance on any forward looking statement. The forward looking statements in this announcement reflect views held only as at the date of this announcement.